Susquehanna International Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-27,700
| Closed | -$1.06M | – | 13420 |
|
|
2023
Q2 | $1.06M | Sell |
27,700
-109,200
| -80% | -$2.8M | ﹤0.01% | 6538 |
|
|
2023
Q1 | $3.17M | Buy |
136,900
+112,600
| +463% | +$2.68M | ﹤0.01% | 4214 |
|
|
2022
Q4 | $637K | Sell |
24,300
-223,300
| -90% | -$4.95M | ﹤0.01% | 7247 |
|
|
2022
Q3 | $4.87M | Sell |
247,600
-114,000
| -32% | -$2.29M | ﹤0.01% | 3193 |
|
|
2022
Q2 | $6.32M | Buy |
361,600
+333,600
| +1,191% | +$5.24M | ﹤0.01% | 2815 |
|
|
2022
Q1 | $458K | Buy |
+28,000
| New | +$381K | ﹤0.01% | 9208 |
|
|
2021
Q4 | – | Sell |
-13,000
| Closed | -$166K | – | 14200 |
|
|
2021
Q3 | $166K | Buy |
+13,000
| New | +$171K | ﹤0.01% | 11699 |
|
|
2021
Q1 | – | Sell |
-13,600
| Closed | -$216K | – | 13017 |
|
|
2020
Q4 | $216K | Buy |
+13,600
| New | +$205K | ﹤0.01% | 9922 |
|
|
2020
Q3 | – | Sell |
-17,100
| Closed | -$198K | – | 11332 |
|
|
2020
Q2 | $198K | Buy |
17,100
+6,940
| +68% | +$95.7K | ﹤0.01% | 9048 |
|
|
2020
Q1 | $139K | Buy |
+10,160
| New | +$120K | ﹤0.01% | 9064 |
|
|
2019
Q3 | – | Sell |
-8,340
| Closed | -$64K | – | 11024 |
|
|
2019
Q2 | $64K | Sell |
8,340
-3,700
| -31% | -$56.3K | ﹤0.01% | 9779 |
|
|
2019
Q1 | $240K | Buy |
12,040
+6,960
| +137% | +$121K | ﹤0.01% | 7596 |
|
|
2018
Q4 | $67K | Sell |
5,080
-12,840
| -72% | -$257K | ﹤0.01% | 8384 |
|
|
2018
Q3 | $659K | Buy |
17,920
+13,900
| +346% | +$446K | ﹤0.01% | 6037 |
|
|
2018
Q2 | $141K | Sell |
4,020
-3,920
| -49% | -$150K | ﹤0.01% | 8886 |
|
|
2018
Q1 | $369K | Sell |
7,940
-3,000
| -27% | -$110K | ﹤0.01% | 7249 |
|
|
2017
Q4 | $410K | Sell |
10,940
-1,600
| -13% | -$69.9K | ﹤0.01% | 7011 |
|
|
2017
Q3 | $668K | Sell |
12,540
-1,400
| -10% | -$83.2K | ﹤0.01% | 6013 |
|
|
2017
Q2 | $795K | Sell |
13,940
-1,680
| -11% | -$84.3K | ﹤0.01% | 5743 |
|
|
2017
Q1 | $840K | Buy |
15,620
+3,700
| +31% | +$209K | ﹤0.01% | 5498 |
|
|
2016
Q4 | $679K | Sell |
11,920
-1,380
| -10% | -$83.5K | ﹤0.01% | 6348 |
|
|
2016
Q3 | $827K | Buy |
13,300
+420
| +3% | +$29.7K | ﹤0.01% | 5147 |
|
|
2016
Q2 | $728K | Buy |
12,880
+2,920
| +29% | +$177K | ﹤0.01% | 5465 |
|
|
2016
Q1 | $638K | Sell |
9,960
-5,340
| -35% | -$432K | ﹤0.01% | 5956 |
|
|
2015
Q4 | $2.15M | Buy |
+15,300
| New | +$2.08M | ﹤0.01% | 3886 |
|
Susquehanna International Group's KDNY Position: Q3 2023 in Review
Susquehanna International Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 156,194 shares — an estimated $6M sold.
Susquehanna International Group first reported a position in KDNY in Q2 2015 and held it in 20 quarters. The position peaked at $6M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Susquehanna International Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Susquehanna International Group sold 156,194 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $6M.
- Susquehanna International Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 20 quarters.
- Susquehanna International Group's Chinook Therapeutics, Inc. Common Stock position peaked at $6M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.